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ABSTRACT:
Mantle cell lymphoma (MCL) is a malignant lymphoproliferative B-cell disorder 
that does not occur spontaneously in mice but experimental mice model have been 
developed. Recently two different mice models prone to develop MCL-like lymphomas 
were generated: c-myc-3’RR/Cdk4R24C mice and c-myc-3’RR/p53+/- mice. Comparison of 
their gene expression profiles does not highlight specific differences other than those in 
relation with their specific mutational status (i.e., Cdk4R24C mutation or p53 mutation). 
We propose that similarly to typical human MCL and its blastoid or cyclin-D1 variants 
that correspond to the same genetic entity, MCL-like lymphomas of c-myc-3’RR/
p53+/- mice and c-myc-3’RR/Cdk4R24C mice represent a spectrum of the same entity.
INTRODUCTION
Mantle cell lymphoma (MCL) is a malignant 
lymphoproliferative B-cell disorder derived from naïve 
pregerminal center CD5+ cells [1]. MCL is strongly 
associated with the t(11,14) chromosomal translocation 
leading to overexpression of cyclin D1. Cyclin D1-
negative MCL do no express high amounts of cyclin 
D1 but elevated cyclin D2 or cyclin D3 ones and share 
the same secondary genetic aberrations that typical 
MCL supporting the concept that they correspond 
to the same genetic entity [1]. MCL does not occur 
spontaneously in mice but experimental mice model 
have been developed. Old Eµ-cyclin D1 transgenic 
mice developed CD19+IgM+CD5+CD23- MCL under 
stimulation  by  pristine,  a  pro-inflammatory  tumor 
promoter [2]. Interleukin 14 alpha (IL-14α)/c-myc double 
transgenic mice developed lymphomas reproducing many 
features of blastoid variant of MCL [3]. Recently we 
generated two different mice models prone to develop 
MCL-like  lymphomas.  The  first  one  uses  the  Cdk4-
Arg24Cys (R24C) mutation that abolishes the ability 
of all four INK4 members to bind Cdk4. Disruption of 
Cdk4 regulation by INK4 while c-myc is overexpressed 
in B-cells (in a c-myc-3’RR transgenic background prone 
to develop Burkitt lymphoma (BL)-like lymphomas 
[4]) leads to the development (in double mutant c-myc-
3’RR/Cdk4R24C mice) of lymphoid malignancies closely 
resembling human MCL [5]. The second is relevant 
to the frequent loss of p53 function observed in human 
lymphomas, underscoring its critical role in suppressing 
the emergence of incipient tumors. Double mutant c-myc-
3’RR/p53+/- mice developed a wide pattern of lymphomas 
including MCL-like lymphomas [6]. It remains unclear 
what are the common molecular and genetic pathways 
explaining the convergence of these two mice models 
towards the same lymphoma phenotype. In both situations, 
MCL-like lymphomas express similar membrane 
B-cell differentiation markers (B220+CD19+IgM+IgD+ 
CD5+CD23-) but arise with different kinetics (3 months 
vs 6 months for c-myc-3’RR/p53+/- mice and c-myc-3’RR/
Cdk4R24C mice, respectively), with a different proteomic 
signature  (Cdk6/cyclin  D  complexes  vs  Cdk4/cyclin 
D complexes for c-myc-3’RR/p53+/- mice and c-myc-
3’RR/Cdk4R24C mice, respectively), and in relation with a 










Description A-B A-B A-B
Tppp NM_182839 polymerization promoting protein -5.97 0.03 4.48
Prkcc NM_011102 protein kinase C, gamma -4.35 0.03 4.28
Gchfr NM_177157 GTP cyclohydrolase I feedback regulator -3.91 0.03 4.14
Chit1 NM_027979 chitinase 1 (chitotriosidase) -5.14 0.03 4.11
Ahnak NM_001039959 nucleoprotein (desmoyokin), TV 3 -4.48 0.03 3.95
Trf NM_133977 transferrin -4.41 0.03 3.94
Apoc1 NM_007469 apolipoprotein C-I, TV 1 -3.74 0.03 3.94
Macrod2 NM_028387 MACRO domain containing 2, TV 2 2.89 0.03 3.56
Rfx2 NM_009056 regulatory factor X, TV 2 -3.31 0.03 3.52
Ctse NM_007799 cathepsin E -4.17 0.03 3.46
Cdkn2a NM_009877 cyclin-dependent kinase inhibitor 2A, TV 1 4.17 0.03 3.45
Slc40a1 NM_016917 solute carrier family 40, M 1 -5.21 0.03 3.43
Igf1 NM_010512 insulin-like growth factor 1, TV 1 -3.1 0.03 3.43
Igf2bp3 NM_023670 insulin-like growth factor 2 mRNA binding protein 3 2.85 0.03 3.38
Slc2a6 NM_172659 solute carrier family 2, M 6 2.51 0.03 3.31
Ngfr NM_033217 nerve growth factor receptor -3.13 0.03 3.28
Camk4 NM_009793 calcium/calmodulin-dependent protein kinase IV 3.42 0.03 3.25
Rtn4rl1 NM_177708 reticulon 4 receptor-like 1 -4.58 0.03 3.19
Ear11 NM_053113 eosinophil-associated, ribonuclease A family, M 11 -2.64 0.03 3.14
Ccnb1 NM_172301 cyclin B1 2.9 0.03 3.11
Rasal1 NM_013832 RAS protein activator like 1 (GAP1 like) 2.67 0.03 3.10
As3mt NM_020577 arsenic (+3 oxidation state) methyltransferase -2.71 0.03 3.08
Ppl NM_008909 periplakin -2.79 0.03 3.06
Spic NM_011461 spi-C transcription factor -3.85 0.03 2.97
Eif2c2 NM_153178 eukaryotic translation initiation factor 2C 3.42 0.03 2.95
Ak4 NM_001177602 adenylate kinase 4, TV 1 3.54 0.03 2.93
Timeless NM_001164081 timeless homolog (Drosophila),TV 4 2.57 0.03 2.89
Rgs12 NM_173402 regulator of G-protein signaling 12, TV 1 3.1 0.03 2.86
Ccr3 NM_009914 chemokine (C-C motif) receptor 3 -2.74 0.03 2.79
Mrap NM_029844 melanocortin 2 receptor accessory protein -2.36 0.03 2.79
Cdc20 NM_023223 cell division cycle 20 homolog 2.26 0.03 2.77
Adarb1 NM_001024837 adenosine deaminase B1, TV 2 2.25 0.03 2.75
Cotl1 NM_028071 coactosin-like 1 (Dictyostelium) -2.13 0.03 2.69
Trip13 NM_027182 thyroid hormone receptor interactor 13 2.3 0.03 2.65
Atp6v1c2 NM_133699 ATPase, lysosomal V1 subunit C2, TV 2 -2.83 0.03 2.58
Slc43a3 NM_021398 solute carrier family 43, M 3 3.27 0.03 2.46
Sbk1 NM_145587 SH3-binding kinase 1 -2.45 0.03 2.38
Vcam1 NM_011693 vascular cell adhesion molecule 1 -4.91 0.03 2.37
Kcnj16 NM_010604
potassium inwardly-rectifying channel, subfamily J, M 
16
-2 0.03 2.33
Lmo1 NM_057173 LIM domain only 1 2.01 0.03 2.30
Osbpl5 NM_024289 oxysterol binding protein-like 5, TV 1 -2.17 0.03 2.30
Tmco6 NM_028036 transmembrane and coiled-coil domains 6 -2.01 0.03 2.30
Serpinb3c NM_201363 serine (or cysteine) peptidase inhibitor, clade B, M 3C 2.63 0.03 2.25
Trim11 NM_053168 tripartite motif-containing 11 -2.06 0.03 2.24
Slc16a9 NM_025807 solute carrier family 16 , M 9 -2.07 0.03 2.23
Fxyd6 NM_022004 FXYD domain-containing ion transport regulator 6 2.13 0.03 2.22
Gstm5 NM_010360 glutathione S-transferase, mu 5 2.52 0.03 2.19




ring finger protein 157 2.52 0.03 2.124
Nek2 NM_010892
NIMA (never in mitosis gene a)-related expressed 
kinase 2
2.57 0.03 2.11
C6 NM_016704 complement component 6 -2.18 0.03 2.05
H60a NM_010400 histocompatibility 60a -6.18 0.03 2.04
septin3 NM_011889 septin 3 -6.18 0.03 2.04
Ear10 NM_053112 eosinophil-associated, ribonuclease A family, M 10 -2.2 0.03 1.99
Kctd17 NM_001081367
potassium channel tetramerisation domain containing 
17
3.64 0.03 1.91
Casc4 NM_001205369 cancer susceptibility candidate 4, TV 3 2.44 0.03 1.89
Tcp11l2 NM_146008 t-complex 11 like 2 -2.88 0.03 1.83
Mybl2 NM_008652 myeloblastosis oncogene-like 2 2.16 0.03 1.83
Prkar2a NM_008924
protein kinase, cAMP dependent regulatory, type II 
alpha
2.1 0.03 1.81
Tcp11 NM_013687 t-complex protein 11, TV 1 -2.04 0.03 1.81
Trerf1 NM_172622 transcriptional regulating factor 1,TV 2 3.07 0.03 1.80
Pvrl2 NM_008990 poliovirus receptor-related 2, TV 1 -4.17 0.03 1.78
Prkar2b NM_011158
protein kinase, cAMP dependent regulatory, type II 
beta
-3.46 0.03 1.78
Melk NM_010790 maternal embryonic leucine zipper kinase 2.23 0.03 1.75
Cdca3 NM_013538 cell division cycle associated 3 2.21 0.03 1.74
B3gnt8 NM_146184
betaGal beta-1,3-N-acetylglucosaminyltransferase 8, 
TV 1
-2.19 0.03 1.71
Nradd NM_026012 neurotrophin receptor associated death domain 2.29 0.03 1.68
S100a5 NM_011312 S100 calcium binding protein A5 -2.38 0.03 1.68
Antxr1 NM_054041 anthrax toxin receptor 1 2.25 0.04 1.64




A kinase (PRKA) anchor protein 13 -2.23 0.04 1.62
Ebf3 NM_010096 early B-cell factor 3, TV 3 2.86 0.04 1.60
Tk1 NM_009387 thymidine kinase 1 2.46 0.04 1.57
Rgs11 NM_001081069 regulator of G-protein signaling 11 -2.22 0.04 1.57
Gm4910 XM_141816 predicted pseudogene 4910 -2.22 0.04 1.56
Ell3 NM_145973 elongation factor RNA polymerase II-like 3 -3.12 0.04 1.55
Etl4 NM_001081006 enhancer trap locus 4, transcript variant c 3.4 0.04 1.50
Syce2 NM_027954





NR_004442 ribosomal protein L22 like 1 pseudogene -2.17 0.04 1.38
Sorcs2 NM_030889 sortilin-related VPS10 domain containing receptor 2 -2.12 0.04 1.38
Crip2 NM_024223 cysteine rich protein 2 -4.51 0.04 1.37
Wnk2 NM_029361 WNK lysine deficient protein kinase 2 3.76 0.04 1.36
Samd9l NM_010156 sterile alpha motif domain containing 9-like -2.09 0.04 1.36
Hoxb6 NM_008269 homeobox B6 -2.23 0.04 1.35
Rpl22l1 NM_026517 ribosomal protein L22 like 1 -2.02 0.04 1.34
Crip1 NM_007763 cysteine-rich protein 1 -4.05 0.04 1.31
Enkur NM_027728 enkurin -3.01 0.04 1.30
Ear2 NM_007895 eosinophil-associated, ribonuclease A family,M 2 -3.45 0.04 1.29
Cdca5 NM_026410 cell division cycle associated 5 2.04 0.04 1.23
Mrc1 NM_008625 mannose receptor, C type 1 -2.61 0.04 1.22
Ear12 NM_001012766 eosinophil-associated, ribonuclease A family, M 12 -2.29 0.04 1.20
Ehf NM_007914 ets homologous factor 2.89 0.04 1.16
Ssbp2 NM_024272 single-stranded DNA binding protein 2, TV 2 2.49 0.04 1.14
Phlda3 NM_013750 pleckstrin homology-like domain, family A, M 3 -4.08 0.04 1.14
Whsc1 NM_001177884 Wolf-Hirschhorn syndrome candidate 1, TV 3 2.16 0.04 1.11
Gm2a NM_010299 GM2 ganglioside activator protein -2.21 0.04 1.11
Armc2 NM_001034858 armadillo repeat containing 2 3.03 0.04 1.09
Comparison of transcriptoma of c-myc-3’RR/Cdk4R24C and c-myc-3’RR/p53+/- MCL-like lymphomas. Among these 44,000 genes, 176 
significantly differed. A Log score >2, a Log ratio >2 or <-2 and a p<0.05 was used as cut of. A: c-myc-3’RR/p53+/- MCL-like lymphomas; B: c-
myc-3’RR/Cdk4R24C MCL-like lymphomas; M: member; TV: transcript variant. 
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of Cdk4 regulation by INK4). Gene arrays have proven 
effective in establishing molecularly defined subgroups 
within defined tumor entities. We explored the potential 
similar biological entity of these two mice models of 
MCL-like lymphomas by comparing their gene expression 
profiles.
MATERIAL AND METHODS
Our research has been approved by the ethics 
committee review board of our University (Limoges, 
France) and hospital (CHU Dupuytren, Limoges, France). 
Animal works has been conducted according to French 
laws. c-myc-3’RR transgenic mice are prone to BL-like 
lymphomas [4]. In c-myc-3’RR mice, c-myc is specifically 
expressed from the pre-B to the mature B-cell stages; the 
3’RR being active in late B cell lymphopoiesis [7-9]. 
Generation of c-myc-3’RR/Cdk4R24C and c-myc-3’RR/
p53+/- mice in similar genetic background and their 
MCL-like lymphoma development have been previously 
reported [5, 6]. mRNA was extracted from MCL-like 
lymphoma cases by sorting tumoral cells with CD19-
coupled beads (Miltenyi Biotech, Bergisch Gladbach, 
Germany). Microarray experiments were done in “Nice - 
Sophia Antipolis Microarray Facility” (France). Statistical 
analysis was made with the Bioconductor open source 
software, particularly its Limma package. The microarray 
data presented in this article have been submitted to the 
Gene Expression Omnibus database (www.ncbi.nlm.nih.
gov/geo/) under the accession numbers GSE36808.
RESULTS AND DISCUSSION
The gene expression profile of MCL-like lymphomas 
of c-myc-3’RR/Cdk4R24C mice was compared with the 
one of c-myc-3’RR/p53+/- mice using an array of 44,000 
genes. A Log score >2, a Log ratio >2 or <-2 and a p<0.05 
was used as cut of. Among these 44,000 genes, only 176 
significantly differed (Tables 1, 2, 3 and 4). Noticeably, 
differential expression of multiple genes involved in 
growth, metabolism and signalling (97/176, 55.1%, Table 
1),  diabetes  and  obesity  (31/176,  17.6%, Table  2)and 
cellular architecture (23/176, 13.0%, Table 3) were found. 
Thirty two unknown genes significantly differed (32/176, 
18.1%, Table 4). Of note some genes can be found both in 
Table 1, 2 and/or 3.
Differences concerning genes involved in diabetes 
and obesity (such as Abcc8, Trf, apoc1 and IGF-1) appear 
directly linked to the Cdk4R24C mutation since loss of Cdk4 
expression  causes  insulin-deficient  diabetes  and  Cdk4 
activation  results  in  β-islet  cell  hyperplasia  [10]. The 
metabolic and endocrinic changes resulting from diabetes 
and obesity may dysregulate DNA repair, gene functions 
and cell mutation rate favouring neoplastic transformation 
and leading to hematologic malignancy and cancer [11]. 
For example IGF-1 (insulin growth factor 1) transcripts 
are markedly elevated in MCL-like lymphomas of 
c-myc-3’RR/Cdk4R24C mice; IGF-1 involvement being 
well documented in cancer [11]. Differences concerning 
genes implicated in the growth and signalling processes 
could be explained by the Cdk4R24C and p53 mutations 
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As3mt NM_020577 arsenic (+3 oxidation state) methyltransferase -2.71 0.03 3.08
Ppl NM_008909 periplakin -2.79 0.03 3.06
Spic NM_011461 spi-C transcription factor -3.85 0.03 2.97
Eif2c2 NM_153178 eukaryotic translation initiation factor 2C 3.42 0.03 2.95
Ak4 NM_001177602 adenylate kinase 4, TV 1 3.54 0.03 2.93
Timeless NM_001164081 timeless homolog (Drosophila),TV 4 2.57 0.03 2.89
Rgs12 NM_173402 regulator of G-protein signaling 12, TV 1 3.1 0.03 2.86
Ccr3 NM_009914 chemokine (C-C motif) receptor 3 -2.74 0.03 2.79
Mrap NM_029844 melanocortin 2 receptor accessory protein -2.36 0.03 2.79
Cdc20 NM_023223 cell division cycle 20 homolog 2.26 0.03 2.77
Adarb1 NM_001024837 adenosine deaminase B1, TV 2 2.25 0.03 2.75
Cotl1 NM_028071 coactosin-like 1 (Dictyostelium) -2.13 0.03 2.69
Trip13 NM_027182 thyroid hormone receptor interactor 13 2.3 0.03 2.65
Atp6v1c2 NM_133699 ATPase, lysosomal V1 subunit C2, TV 2 -2.83 0.03 2.58
Slc43a3 NM_021398 solute carrier family 43, M 3 3.27 0.03 2.46
Sbk1 NM_145587 SH3-binding kinase 1 -2.45 0.03 2.38
Vcam1 NM_011693 vascular cell adhesion molecule 1 -4.91 0.03 2.37
Kcnj16 NM_010604
potassium inwardly-rectifying channel, subfamily J, M 
16
-2 0.03 2.33
Lmo1 NM_057173 LIM domain only 1 2.01 0.03 2.30
Osbpl5 NM_024289 oxysterol binding protein-like 5, TV 1 -2.17 0.03 2.30
Tmco6 NM_028036 transmembrane and coiled-coil domains 6 -2.01 0.03 2.30
Serpinb3c NM_201363 serine (or cysteine) peptidase inhibitor, clade B, M 3C 2.63 0.03 2.25
Trim11 NM_053168 tripartite motif-containing 11 -2.06 0.03 2.24
Slc16a9 NM_025807 solute carrier family 16 , M 9 -2.07 0.03 2.23
Fxyd6 NM_022004 FXYD domain-containing ion transport regulator 6 2.13 0.03 2.22
Gstm5 NM_010360 glutathione S-transferase, mu 5 2.52 0.03 2.19




ring finger protein 157 2.52 0.03 2.124
Nek2 NM_010892
NIMA (never in mitosis gene a)-related expressed 
kinase 2
2.57 0.03 2.11
C6 NM_016704 complement component 6 -2.18 0.03 2.05
H60a NM_010400 histocompatibility 60a -6.18 0.03 2.04
septin3 NM_011889 septin 3 -6.18 0.03 2.04
Ear10 NM_053112 eosinophil-associated, ribonuclease A family, M 10 -2.2 0.03 1.99
Kctd17 NM_001081367
potassium channel tetramerisation domain containing 
17
3.64 0.03 1.91
Casc4 NM_001205369 cancer susceptibility candidate 4, TV 3 2.44 0.03 1.89
Tcp11l2 NM_146008 t-complex 11 like 2 -2.88 0.03 1.83
Mybl2 NM_008652 myeloblastosis oncogene-like 2 2.16 0.03 1.83
Prkar2a NM_008924
protein kinase, cAMP dependent regulatory, type II 
alpha
2.1 0.03 1.81
Tcp11 NM_013687 t-complex protein 11, TV 1 -2.04 0.03 1.81
Trerf1 NM_172622 transcriptional regulating factor 1,TV 2 3.07 0.03 1.80
Pvrl2 NM_008990 poliovirus receptor-related 2, TV 1 -4.17 0.03 1.78
Prkar2b NM_011158
protein kinase, cAMP dependent regulatory, type II 
beta
-3.46 0.03 1.78
Melk NM_010790 maternal embryonic leucine zipper kinase 2.23 0.03 1.75
Cdca3 NM_013538 cell division cycle associated 3 2.21 0.03 1.74
B3gnt8 NM_146184
betaGal beta-1,3-N-acetylglucosaminyltransferase 8, 
TV 1
-2.19 0.03 1.71
Nradd NM_026012 neurotrophin receptor associated death domain 2.29 0.03 1.68
S100a5 NM_011312 S100 calcium binding protein A5 -2.38 0.03 1.68
Antxr1 NM_054041 anthrax toxin receptor 1 2.25 0.04 1.64




A kinase (PRKA) anchor protein 13 -2.23 0.04 1.62
Ebf3 NM_010096 early B-cell factor 3, TV 3 2.86 0.04 1.60
Tk1 NM_009387 thymidine kinase 1 2.46 0.04 1.57
Rgs11 NM_001081069 regulator of G-protein signaling 11 -2.22 0.04 1.57
Gm4910 XM_141816 predicted pseudogene 4910 -2.22 0.04 1.56
Ell3 NM_145973 elongation factor RNA polymerase II-like 3 -3.12 0.04 1.55
Etl4 NM_001081006 enhancer trap locus 4, transcript variant c 3.4 0.04 1.50
Syce2 NM_027954





NR_004442 ribosomal protein L22 like 1 pseudogene -2.17 0.04 1.38
Sorcs2 NM_030889 sortilin-related VPS10 domain containing receptor 2 -2.12 0.04 1.38
Crip2 NM_024223 cysteine rich protein 2 -4.51 0.04 1.37
Wnk2 NM_029361 WNK lysine deficient protein kinase 2 3.76 0.04 1.36
Samd9l NM_010156 sterile alpha motif domain containing 9-like -2.09 0.04 1.36
Hoxb6 NM_008269 homeobox B6 -2.23 0.04 1.35
Rpl22l1 NM_026517 ribosomal protein L22 like 1 -2.02 0.04 1.34
Crip1 NM_007763 cysteine-rich protein 1 -4.05 0.04 1.31
Enkur NM_027728 enkurin -3.01 0.04 1.30
Ear2 NM_007895 eosinophil-associated, ribonuclease A family,M 2 -3.45 0.04 1.29
Cdca5 NM_026410 cell division cycle associated 5 2.04 0.04 1.23
Mrc1 NM_008625 mannose receptor, C type 1 -2.61 0.04 1.22
Ear12 NM_001012766 eosinophil-associated, ribonuclease A family, M 12 -2.29 0.04 1.20
Ehf NM_007914 ets homologous factor 2.89 0.04 1.16
Ssbp2 NM_024272 single-stranded DNA binding protein 2, TV 2 2.49 0.04 1.14
Phlda3 NM_013750 pleckstrin homology-like domain, family A, M 3 -4.08 0.04 1.14
Whsc1 NM_001177884 Wolf-Hirschhorn syndrome candidate 1, TV 3 2.16 0.04 1.11
Gm2a NM_010299 GM2 ganglioside activator protein -2.21 0.04 1.11
Armc2 NM_001034858 armadillo repeat containing 2 3.03 0.04 1.09
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Description A-B A-B A-B
Abcc8 NM_011510 ATP-binding cassette, sub-family C,  M 8 4.11 0.03 4.02
Ahnak NM_001039959 nucleoprotein (desmoyokin), TV 3 -4.48 0.03 3.95
Trf NM_133977 transferrin -4.41 0.03 3.94
Apoc1 NM_007469 apolipoprotein C-I, TV 1 -3.74 0.03 3.94
Cr2 NM_007758 complement receptor 2 -3.62 0.03 3.77
Cdkn2a NM_009877 cyclin-dependent kinase inhibitor 2A, TV 1 4.17 0.03 3.45
Gfra2 NM_008115 glial derived neurotrophic factor family receptor alpha 2 -4.48 0.03 3.44
Igf1 NM_010512 insulin-like growth factor 1, TV  1 -3.1 0.03 3.43
Igf2bp3 NM_023670 insulin-like growth factor 2 mRNA binding protein 3 2.85 0.03 3.38
Hmox1 NM_010442 heme oxygenase (decycling) 1 -3.87 0.03 3.29
Gstt1 NM_008185 glutathione S-transferase, theta 1 2.7 0.03 3.17
Rcan2 NM_207649 regulator of calcineurin 2, TV  1 3.87 0.03 3.16
Tub NM_021885 tubby candidate gene -3.29 0.03 3.13
Osbpl3 NM_001163645 oxysterol binding protein-like 3, TV 2 2.49 0.03 2.99
Mgll NM_001166251 monoglyceride lipase, TV 1 2.1 0.03 2.85
Srd5a1 NM_175283 steroid 5 alpha-reductase 1 3.31 0.03 2.42
Rgs16 NM_011267 regulator of G-protein signaling 16 2.96 0.03 2.23
Cbs NM_144855 cystathionine beta-synthase, TV 1 3.82 0.03 2.19
Alox5 NM_009662 arachidonate 5-lipoxygenase 2.18 0.03 2.19
Pdk1 NM_172665 pyruvate dehydrogenase kinase, isoenzyme 1 2.68 0.03 1.96
Me1 NM_001198933 malic enzyme 1, TV 2 2.49 0.03 1.90
Mef2b NM_001045484 myocyte enhancer factor 2B, TV 2 3.17 0.03 1.88
Foxp2
ENSMUST00000
118133 forkhead box P2 [ENSMUST00000118133] 2.08 0.03 1.79
Aurka NM_011497 aurora kinase A 2.07 0.03 1.70
Ube2e2 NM_144839 ubiquitin-conjugating enzyme E2E 2 3.03 0.03 1.66
Bmpr1a NM_009758 bone morphogenetic protein receptor, type 1A 3.25 0.04 1.45
Kcnj10 NM_001039484 potassium inwardly-rectifying channel, subfamily J, M 10 -3.04 0.04 1.39
Hfe NM_010424 hemochromatosis -2.07 0.04 1.33
Pdss1 NM_019501 prenyl (solanesyl) diphosphate synthase, subunit 1 2.06 0.04 1.07
Hpgd NM_008278 hydroxyprostaglandin dehydrogenase 15 -2.94 0.04 1.04
Fabp5 NM_010634 fatty  acid binding protein 5 2.65 0.04 1.02
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cycle regulatory genes Ccnb1 and Cdc20 in MCL-like 
lymphomas of c-myc-3’RR/p53+/- mice appear directly 
linked to the p53+/- mutation that increases the rate and 
occurrence of c-myc-induced lymphomas [6, 12]. Indeed, 
Ccnb1 overexpression in lymphomas is caused by non-
functional p53 [13], while Cdc20 is negatively regulated 
by p53 [14]. In turn the down regulation of the Cdk4 
inhibitor Cdkn2a in MCL-like lymphomas of c-myc-
3’RR/Cdk4R24C mice appears related to its inefficiency in 
Cdk4R24C mice. As a consequence of a higher proliferation 
rate, several genes implicated in cell metabolism (such 
as Adarb1, Lmo1, AK4, Slc2a4) and nuclear membrane 
or chromosome stability (such as Lmnb1 and Cenpi) are 
higher in MCL-like lymphomas of c-myc-3’RR/p53+/- 
mice than in MCL-like lymphomas of c-myc-3’RR/
Cdk4R24C mice. Finally and also linked to a higher rate of 
proliferation, several differences are found concerning 
genes implicated in cellular architecture especially on 
the actin and microtubule cytoskeletons (such as advillin 
Kif18b, Mtus2, Tubb2b, Mtap2, Stmn1), key players that 
underpin growth processes [15].
MCL-like lymphomas of c-myc-3’RR/p53+/- mice are 
more aggressive than those of c-myc-3’RR/Cdk4R24C mice 
despite similar flow cytometry profiles [5, 6]. Comparison 
of their gene expression profiles explains this difference by 
a marked overexpression of several cell cycle regulatory 
genes. Gene expression profiles do not highlight other 
specific differences other than those in relation with their 
specific mutational status (i.e., Cdk4R24C or p53 mutations). 
We propose that similarly to typical human MCL and its 









Description A-B A-B A-B
Ahnak NM_001039959 nucleoprotein (desmoyokin), TV 3 -4.48 0.03 3.95
Myadm NM_016969 myeloid-associated differentiation marker, TV 4 -5.5 0.03 3.69
Stab2 NM_138673 stabilin 2 -3.39 0.03 3.50
Fcna NM_007995 ficolin A -4.8 0.03 3.46
Avil NM_009635 advillin 4.05 0.03 3.42
Ctnnbip1 NM_023465 catenin beta interacting protein 1, TV 1 2.32 0.03 2.85
Ncan NM_007789 neurocan 2.23 0.03 2.78
Kif18b NM_197959 kinesin family member 18B 2.17 0.03 2.68
Pcolce2 NM_029620 procollagen C-endopeptidase  enhancer 2 -2.11 0.03 2.61
Spock2 NM_052994 sparc/osteonectin 2.36 0.03 2.50
Thbs3 NM_013691 thrombospondin 3 -4.07 0.03 2.37
Lmnb1 NM_010721 lamin B1 2.01 0.03 2.30
Zwilch NM_026507 Zwilch, kinetochore associated 2.25 0.03 2.19
Cd97 NM_011925 CD97 antigen, TV 1 -3.62 0.03 2.07
Mtus2 NM_029920 microtubule associated tumor suppressor candidate 2 -4.03 0.03 1.95
Cenpi NM_145924 centromere protein I 2.11 0.03 1.94
Mef2b NM_001045484 myocyte enhancer  factor 2B, TV 2 3.17 0.03 1.88
Dscaml1 NM_001081270 down syndrome cell adhesion molecule-like 1 -2.58 0.03 1.81
Tubb2b NM_023716 tubulin, beta 2B -4.58 0.03 1.75
Spc25 NM_001199123 NDC80 kinetochore complex component, TV 1 2.23 0.04 1.56
Mtap2 NM_001039934 microtubule-associated protein 2, TV 1 2.24 0.04 1.56
Stmn1 NM_019641 stathmin 1 2.77 0.04 1.39
Slmo1 NM_144867 slowmo homolog 1 4.5 0.04 1.17
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Name Description A-B A-B A-B
Pqlc1 NM_001164420 PQ loop repeat containing 1, TV 2 -3.62 0.03 3.97
NAP101497-1 same unknown -2.54 0.03 3.09
LOC100502767 XR_104684 hypothetical LOC100502767 3.01 0.03 3.04
A_55_P1973560 same unknown 2.29 0.03 2.99
Ng23 NM_023893 Ng23 protein 4.68 0.03 2.92
A_55_P2137023 same unknown 2.64 0.03 2.87
ENSMUST000001
03452
same predicted gene 16886 -2.55 0.03 2.75
Frmd5 NM_172673 FERM domain containing 5 2.51 0.03 2.56
4931429I11Rik NM_001081121 RIKEN cDNA 4931429I11 gene -4.04 0.03 2.46
5730416F02Rik NR_033596 RIKEN cDNA 5730416F02 gene -2.66 0.03 2.28
ENSMUST000000
98678
same RIKEN cDNA D930028M14 gene -2.44 0.03 2.16
ENSMUST000001
03381
same predicted gene 16944 -2.54 0.03 2.15
ENSMUST000001
03341
same predicted gene 16729 -5.03 0.03 2.00
Clip3 NM_001081114 CAP-GLY domain containing linker protein 3 3.96 0.03 1.89
ENSMUST000001
03314
same predicted gene 16798 -4.33 0.03 1.80
ENSMUST000001
03348
same predicted gene 1502 -4.52 0.03 1.76
Cd2 NM_013486 CD2 antigen -2.97 0.03 1.72
9030409G11Rik NM_001109685 RIKEN cDNA 9030409G11 gene, TV 3 2.64 0.03 1.69
ENSMUST000001
03444
same predicted gene 16971 -2.46 0.03 1.69
Lrrc23 NM_013588 leucine rich repeat containing 23 -3.82 0.03 1.67
Sssca1 NM_020491 Sjogren's syndrome/scleroderma autoantigen 1 homolog 2.06 0.04 1.64
ENSMUST000001
03316
same predicted gene 5571 -3.83 0.04 1.59
Gm3227 XR_105936 predicted gene 3227 -2.99 0.04 1.46
C77080 NM_001033189 expressed sequence C77080 -3.6 0.04 1.44
2810025M15Rik NR_027984 RIKEN cDNA 2810025M15 gene 2.05 0.04 1.25
2200002J24Rik NM_026961 RIKEN cDNA 2200002J24 gene 2.24 0.04 1.25
6030419C18Rik NM_176921 RIKEN cDNA 6030419C18 gene 2.42 0.04 1.20
ENSMUST000001
03493
same predicted gene 16694  -2.37 0.04 1.16
A_55_P2040519 A_55_P2040519 unknown 2.63 0.04 1.14
A_55_P2121294 same unknown -2.46 0.04 1.12
D330028D13Rik NM_172727 RIKEN cDNA D330028D13 gene, TV 1 2.05 0.04 1.11
LOC100502627 BC058714 cDNA clone IMAGE:6842867 2.26 0.04 1.01
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blastoid or cyclin-D1 variants that correspond to the same 
genetic entity [1], MCL-like lymphomas of c-myc-3’RR/
p53+/- mice and c-myc-3’RR/Cdk4R24C mice represent 
a spectrum of the same entity. Our results indicate that 
deregulation of two different signalling pathways within 
a single B cell entity can lead to the emergence of a 
unique lymphoma phenotype carrying different oncogenic 
stigmas. These different oncogenic stigmas explain 
differences concerning the proliferative and/or apoptotic 
status of the lymphoma and thus potential differential 
responses to treatment. Tumor transcriptoma analysis and 
tumor DNA sequence analysis could thus become useful 
laboratory tests paving the way towards personalized 
treatments [16].
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